Bright Minds Biosciences Appoints New Chief Medical Officer
Ticker: DRUG · Form: 6-K · Filed: Jan 8, 2025 · CIK: 1827401
Sentiment: neutral
Topics: executive-appointment, personnel, biotech
TL;DR
Bright Minds adds pharma vet Stephen Collins as CMO, aiming to boost drug pipeline.
AI Summary
Bright Minds Biosciences Inc. announced on January 7, 2025, the appointment of Stephen Collins, M.D., Ph.D., as its new Chief Medical Officer. Dr. Collins brings extensive experience in pharmaceutical development and clinical strategy, having previously held leadership roles at companies like Merck and Pfizer.
Why It Matters
The appointment of a seasoned Chief Medical Officer like Dr. Collins could accelerate the company's drug development pipeline and enhance its clinical trial strategies.
Risk Assessment
Risk Level: low — This filing is a routine announcement of an executive appointment and does not contain significant financial or operational changes.
Key Players & Entities
- Bright Minds Biosciences Inc. (company) — Registrant
- Stephen Collins, M.D., Ph.D. (person) — Appointed Chief Medical Officer
- January 7, 2025 (date) — Date of News Release
- Merck (company) — Previous employer of Dr. Collins
- Pfizer (company) — Previous employer of Dr. Collins
- Ian McDonald (person) — President and Chief Executive Officer
FAQ
What is the primary purpose of this Form 6-K filing?
This Form 6-K filing is to submit a news release dated January 7, 2025, announcing the appointment of Stephen Collins, M.D., Ph.D., as Chief Medical Officer.
Who is Stephen Collins, M.D., Ph.D., and what is his new role?
Stephen Collins, M.D., Ph.D., has been appointed as the new Chief Medical Officer of Bright Minds Biosciences Inc.
When was the news release submitted with this filing?
The news release was dated January 7, 2025, and submitted as part of this Form 6-K filing.
What is Bright Minds Biosciences Inc.'s principal executive office address?
The principal executive office of Bright Minds Biosciences Inc. is located at 19 Vestry Street, New York, NY 10013.
Who signed the Form 6-K on behalf of Bright Minds Biosciences Inc.?
Ian McDonald, President and Chief Executive Officer, signed the Form 6-K on behalf of Bright Minds Biosciences Inc.
Filing Stats: 152 words · 1 min read · ~1 pages · Grade level 10.8 · Accepted 2025-01-07 18:46:41
Filing Documents
- f6k-20250107im.htm (6-K) — 4KB
- ex991-20250107.htm (EX-99.1) — 13KB
- 0001183740-25-000008.txt ( ) — 19KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F [ X ] Form 40-F [ ] SUBMITTED HEREWITH Exhibits 99.1 News Release dated January 7, 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BRIGHT MINDS BIOSCIENCES INC. /s/ Ian McDonald __________________________ Ian McDonald President and Chief Executive Officer Date: January 7, 2025